(Alliance News) - Synairgen PLC on Wednesday said a first patient in the UK has been dosed in a trial of SNG001, the respiratory drug discovery firm's potential Covid-19 treatment.
Shares in the company were 8.0% higher at 166.35 pence each in London in morning trading.
The Southampton-based firm's SNG001 medication is an inhaled form of interferon beta-1a, a protein with anti-viral properties.
The SG018 trial, being in conducted in about 20 countries, has enrolled over 600 Covid-19 patients and is in phase 3.
"We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective. We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis," Chief Executive Officer Richard Marsden said.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Synairgen (SNG)